

## Curriculum Vitae Europass



### Personal Information

First name/Surname **Maria-Ancuta Jurj**  
 Address 23 Gh Marinescu Street, 400012 Cluj-Napoca (Romania)  
 Mobile Number +40 374834810  
 E-mail Address [ancajurj15@gmail.com](mailto:ancajurj15@gmail.com), [anca.jurj@umfcluj.ro](mailto:anca.jurj@umfcluj.ro)  
 Date of birth 15 August 1990

### Work Experience

<p>Dates</p> <p>Occupation and position held</p> <p>Main activities and responsibilities</p> <p>Employer's name and locality</p> <p>Type of business or sector</p>	<p>01.04.2016 – present</p> <p><b>Chemist</b></p> <p>Cell cultures, Exosomes, Flow Cytometry, RT-PCR, Proteomics</p> <p>Research Center for Functional Genomic, Biomedicine and Translational Medicine, University of Medicine and Pharmacy „Iuliu Hatieganu”, Cluj-Napoca</p> <p>Research</p>
<p>Dates</p> <p>Occupation and position held</p> <p>Main activities and responsibilities</p> <p>Employer's name and locality</p> <p>Type of business or sector</p>	<p>15.10.2014 – 31.03.2016</p> <p><b>Technician</b></p> <p>Cell cultures, Flow Cytometry, RT-PCR</p> <p>Research Center for Functional Genomic, Biomedicine and Translational Medicine, University of Medicine and Pharmacy „Iuliu Hatieganu”, Cluj-Napoca</p> <p>Research</p>
<p>Dates</p> <p>Occupation and position held</p> <p>Main activities and responsibilities</p> <p>Employer's name and locality</p>	<p>30.04.2014 - 29.09.2014</p> <p><b>Volunteer Technician</b></p> <p>Cell culture, Cytotoxicity assays, Viability tests, Isolation cell</p> <p>Radiotherapy, Tumor and Radiobiology Laboratory, Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca</p>

Type of business or sector	Research
<b>Education and Training</b>	
Dates	1.10.2015 – 25.04.2019
Qualification Awarded	Doctor in Medicine
Education or training organisation's name and locality	University of Medicine and Pharmacy „Iuliu Hatieganu”, Cluj-Napoca
Dates	October 2013 – June 2015
Qualification awarded	Master degree – Organic and Biochemical Process Engineering
Principal subjects / occupational skills	Advanced Biochemistry, Advanced enzymology, Engineering bioprocesses, Stereochemistry of Organic Compounds, The retrosynthetic analysis, Bioinorganic materials and processes, selective biotransformation, Ecological strategies of organic synthesis and organometallic
Education or training organisation's name and locality	Babes-Bolyai University, Faculty of Chemistry and Chemical Engineering, 11 Arany Janos Street, Cluj-Napoca
Dates	September 2009 – June 2013
Qualification awarded	Bachelor degree in Biochemical Engineering
Principal subjects / occupational skills	Biochemistry, Microbiology, Cell Biology and Molecular Genetics, Chemical Kinetics, Organic Chemistry, Electrochemistry, Momentum Transfer and Fluid Mechanics, Enzymatic Technologies, etc.
Education or training organisation's name and locality	Babes-Bolyai University, Faculty of Chemistry and Chemical Engineering, 11 Arany Janos street, Cluj-Napoca
Dates	September 2005 -June 2009
Qualification awarded	Diploma
Education or training organisation's name and locality	School group „Dr. Lazar Chirila”, Baia de Aries, Alba county
<b>Personal Skills</b>	
Mother tongue(s)	Romanian
<b>Other language(s)</b>	English
Communication skills	Communication skills, team work, seriousness, capacity to assimilate new information.
Organisational/managerial skills	Cell culture, proteomics, flow cytometry, PCR, rtPCR, PCR array, high throughput rtPCR pe ViiA7 (IVD), quantification of nucleic acids using the Agilent platform Bioanalyzer, Nanodrop and Qubit, migration and cell proliferation evaluation system using xCELLigence, Analytical Data
Computer skills	Proficiency in the use of MS Windows programs, as well as programs for laboratory equipment.

## Additional Information

**Awards** Diploma of Gold Medal for „Real-time on 3D printed structures – method for diagnosis and therapeutic intervention useful in tissue engineering” at EURO INVENT 10 Edition European Exhibition of Creativity and Innovation, 19 May, 2018, Iasi, Romania.

**Number of publications** 33

**Hirsch index** 9 (Scopus)

**Total Impactor Factor** 99.827

### Research Projects

**CNFIS-FDI - CNFIS-FDI-2019-0666:** „Sustenance and valorification of research of excellence in the domain of personalized medicine by internationalization and increasement of research activities visibility” – member. Period may 2019 – December 2019.

**PN-III-P1-1.1-TE-2016-2213:** „Targeting breast cancer resistance mechanism with combinatorial drug therapy using small molecules and siRNA, in post genomic era”- DRUG\_STORE. Period: 2018-2020.

**POC-P\_37\_796 /2016 ctr 35/01.09.2016:** „Clinical and economic impact of personalized targeted therapies with anti - microARN in reconverting resistance of malignant lung tumors” – CANTEMIR. Period: 2016-2020.

**PN-III-P4-ID-PCE-2016-0795:** „Addressing the complex exposome profile in hormone-dependent cancers of the breast and prostate and its influence on tumoral genome” – ACHILLE. Period: 2017-2019.

**PN-III-P2-2.1-PED-2016-1490:** „Co-transplantation of human derived immune stimulatory macrophages and mezenchymal stem cells for optic nerve regeneration in a glaucoma animal model”. Period: 2017-2018.

**PN-II-RU-TE-2014-4-1783:** „Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site”. Period: 2015-2017.

**PN-II-RU-TE-2014-4-1464 ctr.307/2015:** „TGF  $\beta$  signaling pathway tapering: an alternative to TGFtarget breast cancer therapy”. Period: 2015-2017.

**PN-II-PT-PCCA-2013-4-1959 ctr.193/2014:** „ Non-Invasive Intelligent Systems for Colorectal Cancer Diagnosis and Prognosis Based on Circulating miRNA Integrated in the Clinical Workflow” – INTEL COR. Period: 2014-2017.

**PN-II-RU-TE-2014-4-2426:** „Implementation of multifunctional nanomaterials for the early detection and treatment of acute lymphoblastic leukemia using non-invasive techniques”. Period: 2015 -2017.

**PN-II-RU-TE-2014-4-2951:** „Balancing vegfr2 signaling components levels rescues vascular abnormalities in human hereditary teleangiectasia type 2 mouse model”. Period: 2016-2017.

**PN-II-RU-TE-2014-4-1464:** „Targeting the tgfb pathway: an alternative for breast cancer therapy”. Period: 2015-2017.

### Participation in scientific trainings

January 22th – March 17th 2018: Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, South Africa.

June 6-9th, 2017: „International summer school and joint symposium on flow cytometry”, Research

Institute of the University of Bucharest, Bucharest, Romania.

April 4-8th, 2016: Proteomics training, Department of Biomedicine, University of Bergen, Bergen, Norway.

November 5-6th, 2015: Workshop V Edition „Franco-Roman De Hematologie” Hemlmmum Research Networking Event, Cluj-Napoca;

June 22-24th, 2015: Laboratory of Bio-analytical and Proteomics, Department of Chemistry, Faculty of Science and Technology, University Nova, Caparica, Lisbon – Training in Ultrafast sample Treatment for Proteomics;

Poster presentation

July 5-7th, 2018: Poster section at the conference Young Oncology, The Oncology Institute „Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania

Participation in scientific meetings / congresses / symposia:

March 11-12th, 2016: Congress „Insights in Hematology” The Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca;

September 25th, 2015: Cours „Nanopharmacology in leukemia chemotherapy”, The Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca;

June 29-30th, 2015: Win Symposium 2015;

June 10th, 2015: University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca - The Regulatory Processes Involved in Acceptance of Non-Animal Tests;

May 26th, 2015: Seminars - Pro Analysis Systems „Chromatography and mass spectrometry”;

May 5th, 2015: Symposium “Biobanks role and approach in future research studies medicine precision”;

Book chapters

Pop L, Jurj A, Berindan-Neagoe I, (2016) ‘Aplicatiile secventierea de noua generatie in leucemia mieloida cronica’, Dima D, Tomuleasa C, Trifa A. *Leucemia mileoida cronica. De la terapia cu inhibitori de tirozin kinase la transplant*, Cluj-Napoca, 36-42.

Publications

Tatar AS, **Jurj A**, Tomuleasa C, Florea A, Berindan-Neagoe I, Cialla-May D, Popp J, Astilean S, Boca S. CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia. *Colloids Surf B Biointerfaces*. 2019 Aug 30;184:110478. doi: 10.1016/j.colsurfb.2019.110478. [Epub ahead of print] PubMed PMID: 31541890.

Zanoaga O, Braicu C, **Jurj A**, Rusu A, Buiga R, Berindan-Neagoe I. *Progress in Research on the Role of Flavonoids in Lung Cancer*. *Int J Mol Sci*. 2019 Sep 2;20(17). pii: E4291. doi: 10.3390/ijms20174291. Review. PubMed PMID: 31480720.

Ciocan-Cartita CA, **Jurj A**, Buse M, Gulei D, Braicu C, Raduly L, Cojocneanu R, Pruteanu LL, Iuga CA, Coza O, Berindan-Neagoe I. *The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics"*. *Int J Mol Sci*. 2019 May 25;20(10). pii: E2576. doi: 10.3390/ijms20102576. Review. PubMed PMID: 31130665; PubMed Central PMCID: PMC6567119.

Cismaru CA, Soritau O, **Jurj AM**, Lajos R, Pop B, Bocean C, Albzour B, Baldasici O, Moldovan C, Neagoe IB. *Isolation and Characterization of a Fetal-Maternal Microchimeric Stem Cell Population in Maternal Hair Follicles Long after Parturition*. *Stem Cell Rev Rep*. 2019 Aug;15(4):519-529. doi: 10.1007/s12015-019-09885-4. PubMed PMID: 31123983.

Tat T, **Jurj A**, Selicean C, Pasca S, Ionescu D. *Antiproliferative effects of propofol and lidocaine on the colon adenocarcinoma microenvironment*. *J BUON*. 2019 Jan-Feb;24(1):106-115. PubMed PMID: 30941958.

Budisan L, Gulei D, **Jurj A**, Braicu C, Zanoaga O, Cojocneanu R, Pop L, Raduly L, Barbat A, Moldovan A, Moldovan C, Tigu AB, Ionescu C, Atanasov AG, Irimie A, Berindan-Neagoe I. *Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell Lines-Possible Implications in New Therapeutic Strategies*. *Int J Mol Sci*. 2019 Mar 9;20(5). pii: E1199. doi: 10.3390/ijms20051199. PubMed PMID: 30857282; PubMed Central PMCID: PMC6429399.

Braicu C, Gulei D, Cojocneanu R, Raduly L, **Jurj A**, Knutsen E, Calin GA, Berindan-Neagoe I. *miR-181a/b therapy in lung cancer: reality or myth?* Mol Oncol. 2019 Jan;13(1):9-25. doi: 10.1002/1878-0261.12420. Epub 2019 Jan 3. Review. PubMed PMID: 30548184; PubMed Central PMCID: PMC6322195

Obasi TC, Braicu C, Iacob BC, Bodoki E, **Jurj A**, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R. *Securidaca-saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells.* Cancer Manag Res. 2018 Nov 15;10:5709-5724. doi: 0.2147/CMAR.S163328. eCollection 2018. Erratum in: Cancer Manag Res. 2019 Jan 15;11:691. PubMed PMID: 30532593;

Zaharie F, Pop LA, Petrushev B, **Jurj A**, Muresan MS, Eniu D, Fetica B, Petkov B, Pasca S, Piciu D, Rus I, Deak D, Dima D, Desmirean MS, Tomuleasa C, Berindan-Neagoe I. *Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.* Histol Histopathol. 2018 Nov 23:18067. doi: 10.14670/HH-18-067. [Epub ahead of print] PubMed PMID: 30467824.

Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, **Jurj A**, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I. *Aberrant miRNAs expressed in HER-2 negative breast cancers patient.* J Exp Clin Cancer Res. 2018 Oct 20;37(1):257. doi: 10.1186/s13046-018-0920-2. PubMed PMID: 30342533

**Jurj A**, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghia M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I. *Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.* Crit Rev Clin Lab Sci. 2018 Sep 21:1-15. doi: 10.1080/10408363.2018.1499707. [Epub ahead of print] PubMed PMID: 30238808.

Chira S, Raduly L, Braicu C, **Jurj A**, Cojocneanu-Petric R, Pop L, Pileczki V, Ionescu C, Berindan-Neagoe I. *Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death.* Exp Ther Med. 2018 Aug;16(2):1241-1249. doi: 10.3892/etm.2018.6324. Epub 2018 Jun 19. PubMed PMID: 30116375; PubMed Central PMCID: PMC6090263.

Lajos R, Braicu C, **Jurj A**, Chira S, Cojocneanu-Petric R, Pileczki V, Berindan-Neagoe I. *A miRNAs profile evolution of triple negative breast cancer cells in the presence of a possible adjuvant therapy and senescence inducer.* J BUON. 2018 May-Jun;23(3):692-705. PubMed PMID: 30003739.

Tomuleasa C, Selicean C, Cismas S, **Jurj A**, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghia M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I. *Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.* Crit Rev Clin Lab Sci. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25. PubMed PMID: 29801428.

Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, **Jurj A**, Pop L, Berindan-Neagoe I, Dima D, Kitano S. *Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.* Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review. PubMed PMID: 29515572; PubMed Central PMCID: PMC5825894.

Zanoaga O, **Jurj A**, Raduly L, Cojocneanu-Petric R, Fuentes-Mattei E, Wu O, Braicu C, Gherman CD, Berindan-Neagoe I. *Implications of dietary  $\omega$ -3 and  $\omega$ -6 polyunsaturated fatty acids in breast cancer.* Exp Ther Med. 2018 Feb;15(2):1167-1176. doi: 10.3892/etm.2017.5515. Epub 2017 Nov 16. PubMed PMID: 29434704; PubMed Central PMCID: PMC5776638.

Qian L, Dima D, Berce C, Liu Y, Rus I, Raduly LZ, Liu Y, Petrushev B, Berindan-Neagoe I, Irimie A, Tanase A, **Jurj A**, Shen J, Tomuleasa C. *Protein dysregulation in graft versus host disease.* Oncotarget. 2017 Dec 15;9(1):1483-1491. doi: 10.18632/oncotarget.23276. eCollection 2018 Jan 2. Review. PubMed PMID: 29416707; PubMed Central PMCID: PMC5787452.

Gulei D, Magdo L, **Jurj A**, Raduly L, Cojocneanu-Petric R, Moldovan A, Moldovan C, Florea A, Pasca

S, Pop LA, Moisoiu V, Budisan L, Pop-Bica C, Ciocan C, Buiga R, Muresan MS, Stiufuc R, Ionescu C, Berindan-Neagoe I. *The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression*. Cell Death Dis. 2018 Jan 19;9(2):66. doi: 10.1038/s41419-017-0102-8. PubMed PMID: 29352232; PubMed Central PMCID: PMC5833765.

Boca S, Berce C, **Jurj A**, Petrushev B, Pop L, Gafencu GA, Selicean S, Moisoiu V, Temian D, Micu WT, Astilean S, Braicu C, Tomuleasa C, Berindan-Neagoe I. *Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?* Med Hypotheses. 2017 Nov;109:42-45. doi:10.1016/j.mehy.2017.09.023. Epub 2017 Sep 27. PubMed PMID: 29150291.

**Jurj A**, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. *The new era of nanotechnology, an alternative to change cancer treatment*. Drug Des Devel Ther. 2017 Sep 27;11:2871-2890. doi: 10.2147/DDDT.S142337. eCollection 2017. Review. PubMed PMID: 29033548; PubMed Central PMCID: PMC5628667.

Braicu OL, Budisan L, Buiga R, **Jurj A**, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I. *miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples*. Onco Targets Ther. 2017 Aug 28;10:4225-4238. doi: 10.2147/OTT.S137107. eCollection 2017. PubMed PMID: 28894379; PubMed Central PMCID: PMC5584916.

Nagy-Simon T, Tatar AS, Craciun AM, Vulpoi A, **Jurj MA**, Florea A, Tomuleasa C, Berindan-Neagoe I, Astilean S, Boca S. *Antibody Conjugated, Raman Tagged Hollow Gold-Silver Nanospheres for Specific Targeting and Multimodal Dark-Field/SERS/ Two Photon-FLIM Imaging of CD19(+) B Lymphoblasts*. ACS Appl Mater Interfaces. 2017 Jun 28;9(25):21155-21168. doi: 10.1021/acsami.7b05145. Epub 2017 Jun 15. PubMed PMID: 28574250.

Irimie AI, Sonea L, **Jurj A**, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I. *Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer*. Int J Nanomedicine. 2017 Jun 26;12:4593-4606. doi: 10.2147/IJN.S133219. eCollection 2017.

Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, Frinc I, Trifa A, Berce C, **Jurj A**, Berindan-Neagoe I, Zdrenghia M. *How to Diagnose and Treat a Cancer of Unknown Primary Site*. J Gastrointest Liver Dis. 2017 Mar;26(1):69-79. doi: 10.15403/jgld.2014.1121.261.haz.

**Jurj A**, Tomuleasa C, Tat TT, Berindan-Neagoe I, Vesa SV, Ionescu DC. *Antiproliferative and Apoptotic Effects of Lidocaine on Human Hepatocarcinoma Cells*. A preliminary study. J Gastrointest Liver Dis. 2017 Mar;26(1):45-50. doi: 10.15403/jgld.2014.1121.261.juj.

Tomuleasa C, Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, **Jurj A**, Trifa A, Rosu AM, Pasca S, Magdo L, Zdrenghia M, Dima D, Tanase A, Frinc I, Bojan A, Berindan-Neagoe I, Ghiur G, Ciurea SO. *Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis*. J Cell Physiol. 2017 Mar 11. doi: 10.1002/jcp.25902.

Braicu C, Cojocneanu-Petric R, **Jurj A**, Gulei D, Taranu I, Gras AM, Marin DE, Berindan-Neagoe I. *Microarray based gene expression analysis of Sus Scrofa duodenum exposed to zearalenone: significance to human health*. BMC Genomics. 2016 Aug 17;17:646.

Braicu C, Selicean S, Cojocneanu-Petric R, Lajos R, Balacescu O, Taranu I, Marin DE, Motiu M, **Jurj A**, Achimas-Cadariu P, Berindan-Neagoe I. *Evaluation of cellular and molecular impact of zearalenone and Escherichia coli co-exposure on IPEC-1 cells using microarray technology*. BMC Genomics. 2016 Aug 9;17:576.

Pop LA, Pileczki V, Cojocneanu-Petric RM, Petrut B, Braicu C, **Jurj AM**, Buiga R, Achimas-Cadariu P, Berindan-Neagoe I. *Normalization of gene expression measurement of tissue samples obtained by transurethral resection of bladder tumors*. Onco Targets Ther. 2016 Jun 2;9:3369-80.

Baritchii A, **Jurj A**, Soritau O, Tomuleasa C, Raduly L, Zanoaga O, Cernea D, Braicu C, Neagoe I, Stefan Florian I. *Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma*. J BUON. 2016 Jan-Feb;21(1):199-207.

Petrushev B, Boca S, Simon T, Berce C, Frinc I, Dima D, Selicean S, Gafencu GA, Tanase A, Zdrenghia M, Florea A, Suarasan S, Dima L, Stanciu R, **Jurj A**, Buzoianu A, Cucuianu A, Astilean S, Irimie A,

Tomuleasa C, Berindan-Neagoe I. *Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy*. Int J Nanomedicine. 2016 Feb 15;11:641-60.

Gherman C, Braicu OL, Zanoaga O, **Jurj A**, Pileczki V, Maralani M, Drigla F, Braicu C, Budisan L, Achimas-Cadariu P, Berindan Neagoe I. *Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis*. Mol Cell Biochem. 2016 Feb;413(1-2):189-98.

Zaharie F, Muresan MS, Petrushev B, Berce C, Gafencu GA, Selicean S, **Jurj A**, Cojocneanu-Petric R, Lisencu CI, Pop LA, Pileczki V, Eniu D, Muresan MA, Zaharie R, Berindan-Neagoe I, Tomuleasa C, Irimie A. *Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer*. J Gastrointestin Liver Dis. 2015 Dec;24(4):435-43.

Petric RC, Pop LA, **Jurj A**, Raduly L, Dumitrascu D, Dragos N, Neagoe IB. *Next generation sequencing applications for breast cancer research*. Clujul Med. 2015;88(3):278-87.